Table 2.
Initial treatment regimens for newly diagnosed PCNSL surveyed in the questionnaire.
| Treatment regimens | 74 years old or younger | 75 years old or older | ||
|---|---|---|---|---|
| No. of patients (n = 172) | (%) | No. of patients (n = 86) | (%) | |
| Surgery (biopsy) + HD-MTX therapy | 11 | 6.4 | 12 | 14.0 |
| Surgery (biopsy) + HD-MTX therapy + Tirabrutinib | 2 | 1.2 | 3 | 3.5 |
| Surgery (biopsy) + HD-MTX therapy + ASCT/HDC | 3 | 1.8 | 0 | 0 |
| Surgery (biopsy) + HD-MTX therapy + WBRT | 7 | 4.1 | 5 | 5.9 |
| Surgery (biopsy) + R-MPV therapy | 73 | 42.5 | 46 | 53.5 |
| Surgery (biopsy) + R-MPV therapy + Tirabrutinib | 12 | 7.0 | 8 | 9.4 |
| Surgery (biopsy) + R-MPV therapy + ASCT/HDC | 19 | 11.1 | 0 | 0 |
| Surgery (biopsy) + R-MPV therapy + WBRT | 45 | 26.2 | 12 | 14.0 |
| Number of facilities that responded to the survey: 39 of the 47 JCOG-BTSG-registered centers (83.0%) | ||||
Abbreviation: HD-MTX, high-dose methotrexate; WBRT, whole brain radiotherapy; R-MPV, rituximab, methotrexate, procarbazine, and vincristine; ASCT/HDC, autologous stem cell transplantation/high-dose chemotherapy.